今年，绿色加速器项目的入围企业中有一半来自中国。艾什利·布朗说，这充分体现了中国可持续发展 生态的活力与成熟度。据悉，中科原动力、微构工场和上海电气等中国企业入围第三届百事公司绿色加 速器项目。中科原动力以"新能源+智能化"为核心技术驱动，聚焦农业机器人与智慧农业解决方案；微 构工场的核心技术是PHA(聚羟基脂肪酸酯)生物材料生产技术，这是基于下一代工业生物制造技术 (NGIB)和自研菌种技术开发的新技术。上海电气的核心技术在于将低谷电或弃电进行储存，并在需要 时通过蒸汽释放能量。 中科原动力首席执行官韩威博士表示："我们希望通过利用智能化技术提升精准作业和数字化管理水 平，促进农业的增产、增效、增收；采用新能源技术实现农业生产的低碳排放以及降低农业生产成 本。"据悉，中科原动力的智能电动拖拉机已在中国的马铃薯农场进行试点，助力生产环节的可持续转 型。这些"零排放"智能电动拖拉机旨在大幅减少对周边环境及农作物的污染，同时帮助提升作业效率， 并降低潜在作业成本。企业方面希望加速技术国际化推广，并对接全球市场资源。 微构工场首席执行官欧阳鹏飞介绍，微构工场着力解决传统塑料污染和碳排放双重挑战。"我们正积极 推进各 ...

华熙生物科技股份有限公司 关于 2025 年度"提质增效重回报"专项行动方案的 半年度评估报告 为践行以"投资者为本"的上市公司发展理念，响应上海证券交易所号召， 华熙生物科技股份有限公司（以下简称"公司""华熙生物"）结合企业发展阶 段和行业特点，从聚焦主业、运营管理、科技创新、公司治理、投资者回报等方 面，于 2025 年 4 月 9 日发布了《2025 年度"提质增效重回报"专项行动方案》， 现将行动方案半年度评估情况公告如下： 向好，生产需求稳定增长，高质量发展取得新进展。公司经过多年的摸索和市场 的引导修正，主要的基础研发开始向糖生物学和细胞生物学这两大方向聚集，衰 老干预和再生医学为这两大方向提供了应用研究的丰富场景，这些基础研究和应 用研究成为公司技术创新和产品创新的源泉。最终，合成生物平台为产品转化提 供先进制造能力支持。 聚焦高壁垒科技资产转化，深化消费品业务优势：公司核心基础技术为精准 分子量控制的透明质酸，公司依托与全球高校、研究机构及药企的合作，开展细 胞生物学、糖生物学在衰老干预、组织再生领域的逆向研究，形成了细胞外基质、 细胞间通讯和细胞内三大核心板块。其中，细胞外基质（ECM）的 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 大股东持股的基本情况 证券代码：688203 证券简称：海正生材 公告编号：2025-49 浙江海正生物材料股份有限公司 关于 5%以上股东提前终止减持计划暨减持股份结 果公告 股东名称 中国石化集团资本有限公司 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 √是 □否 股东身份 董事、监事和高级管理人员 □是 √否 其他：/ 持股数量 13,659,494股 持股比例 6.74% 当前持股股份来源 IPO 前取得：13,659,494股 上述减持主体无一致行动人。 二、减持计划的实施结果 （一）大股东因以下事项披露减持计划实施结果： 其他情形：减持计划提前终止 股东名称 中国石化集团资本有限公司 减持计划首次披露日期 2025 年 7 月 1 日 减持数量 844,600股 减持期间 2025 年 8 月 22 日～2025 年 8 月 22 日 减持方式及对应减持数量 大宗交易减持，844,600 股 减持价格区间 11 ...

Group 1 - The company has adjusted the maximum repurchase price from 12 RMB per share to 17 RMB per share and extended the implementation period by 6 months, now ending on February 27, 2026 [16][21][36] - The repurchase plan aims to use self-owned funds and may include special loans for stock repurchase [19][20] - As of the disclosure date, the company has repurchased 1,482,364 shares, accounting for 0.731% of the total share capital, with a total expenditure of approximately 14.29 million RMB [20][21] Group 2 - The company raised a total of 845.17 million RMB from the public offering, with a net amount of 750.86 million RMB after deducting various fees [2][4] - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and used according to regulatory requirements [4][5] - The company has not encountered any abnormal situations regarding the investment projects funded by the raised capital [7][8]

Core Viewpoint - The article discusses the transformative potential of adhesive hydrogels in biomedical applications, emphasizing their inherent tissue adhesion properties and the need for controllable degradation rates to enhance their effectiveness [2][10]. Group 1: Advantages of Adhesive Hydrogels - Adhesive hydrogels possess intrinsic tissue adhesion, eliminating the need for additional fixation, making them promising alternatives to traditional sutures and staples [2]. - They are ideal carriers for delivering functional additives such as cells and drugs, enhancing stability and performance compared to conventional hydrogels [2]. - These hydrogels can be utilized in the production of functional wound dressings to promote tissue regeneration and can also repair other medical devices, reducing secondary tissue damage caused by traditional fixation methods [2]. Group 2: Research Findings - A study published by Professor Bu Yazhong's team at Xi'an Jiaotong University revealed a method to control the degradation of adhesive hydrogels by incorporating succinamide esters [3][8]. - The research demonstrated that by adjusting the degradation rate, therapeutic effects varied across different preclinical scenarios, providing practical guidelines for designing biodegradable materials for specific applications [3][10]. - The study established a correlation between in vitro and in vivo degradation patterns, showing that the optimal degradation rate of adhesive hydrogels depends on their intended use, such as rapid degradation for abdominal adhesion prevention and slow degradation for cardiac surgery [6][8]. Group 3: Implications for Future Research - The controllable degradation method developed in this research can be extended to other biomaterials, potentially broadening the applications of adhesive hydrogels in various medical fields [8][10]. - The findings suggest that the degradation speed can be tailored to match the tissue regeneration needs, exemplified by the use of cryogels for liver injury repair, which first stops bleeding and then promotes liver regeneration [6].

Core Viewpoint - The announcement details the upcoming listing and circulation of 6,390,100 restricted shares of Zhejiang Haizheng Biomaterials Co., Ltd., which will be available for trading on August 18, 2025, following the expiration of the lock-up period for certain shareholders [1][2]. Summary by Sections Listing Details - The total number of shares to be listed is 6,390,100, representing 3.15% of the company's total share capital [2]. - The shares will be available for trading starting on August 18, 2025, due to the preceding non-trading day on August 16, 2025 [1]. Shareholder Information - The restricted shares are held by three entities: Taizhou Jiaojiang Chuanghe Enterprise Management Partnership (Limited Partnership), Taizhou Jiaojiang Chuangyou Enterprise Management Partnership (Limited Partnership), and Taizhou Chuangyi Enterprise Management Service Center (Limited Partnership) [2]. - The lock-up period for these shareholders was set for 36 months from the date of the company's initial public offering [2]. Changes in Share Capital - Since the formation of these restricted shares, there have been no changes in the company's share capital due to profit distribution or capital increase [2]. Commitments from Shareholders - The shareholders have committed not to transfer or manage their shares during the lock-up period and to comply with relevant regulations when reducing their holdings [3][4]. - Any income obtained from violations of these commitments must be returned to the company [3]. Management Commitments - Senior management and core technical personnel have similar commitments regarding their shares, including restrictions on transfers during the lock-up period and specific conditions post-lock-up [5][7]. - If the company's stock price falls below the initial offering price for a specified period, the lock-up period may be automatically extended [9]. Regulatory Compliance - The underwriting institution, CITIC Securities Co., Ltd., has confirmed that the listing of these restricted shares complies with relevant laws and regulations [10][11].

Core Viewpoint - The report outlines the verification opinion of CITIC Construction Investment Securities Co., Ltd. regarding the listing and circulation of restricted shares from the initial public offering (IPO) of Zhejiang Haizheng Biological Materials Co., Ltd. on the Sci-Tech Innovation Board, confirming compliance with relevant regulations and the accuracy of information disclosure [1][8]. Summary by Sections Type of Restricted Shares - The restricted shares being listed are part of the company's IPO, totaling 50,669,517 shares, which were listed on August 16, 2022. The total share capital after the IPO is 202,678,068 shares, with restricted shares accounting for 156,470,896 shares (77.20%) and unrestricted shares for 46,207,172 shares (22.80%) [1]. Shareholder Information - The restricted shares involve three shareholders: Taizhou Jiaojiang Chuanghe Enterprise Management Partnership (Limited Partnership), Taizhou Jiaojiang Chuangyou Enterprise Management Partnership (Limited Partnership), and Taizhou Chuangyi Enterprise Management Service Center (Limited Partnership), holding a total of 6,390,100 shares, representing 3.15% of the current total share capital. The lock-up period for these shares is 36 months from the listing date, expiring on August 16, 2025, with the actual listing date adjusted to August 18, 2025, due to a non-trading day [2][3]. Changes in Share Capital - Since the formation of the restricted shares, there have been no changes in the company's share capital due to profit distribution or capital increase [2]. Commitments by Shareholders - The shareholders have committed not to transfer or manage their shares for 36 months post-listing and to comply with relevant regulations during any future share reductions. Any income from violations will be returned to the company [3][4]. Lock-up Period Extension - The lock-up period for certain shareholders was automatically extended by six months to February 15, 2026, due to the stock price falling below the IPO price for 20 consecutive trading days [5][7]. Total Restricted Shares for Listing - The total number of restricted shares for listing is 6,390,100 shares, with the listing date set for August 18, 2025 [7]. Verification Opinion - The sponsor institution confirms that the listing of the restricted shares complies with the Company Law, Securities Law, and relevant regulations, and that the information disclosure is true, accurate, and complete [8].

Core Viewpoint - The controlling shareholder of Hyaluronic Acid leader Huaxi Biological (688363) plans to increase its stake in the company by investing between 200 million to 300 million yuan, with a maximum purchase price of 70 yuan per share [2][8]. Group 1: Shareholder Actions - Huaxi Xingyu Investment Co., Ltd. intends to increase its shareholding in Huaxi Biological, reflecting confidence in the company's long-term value and its ability to lead industry advancements through foundational research [4][8]. - As of August 7, Huaxi Xingyu directly holds 58.86% of Huaxi Biological, with associated parties holding minor stakes [8]. Group 2: Company Performance and Strategy - Huaxi Biological recently celebrated its 25th anniversary and has experienced both significant growth and challenges over the years [11]. - The company reported its highest performance in 2022, with a net profit of 971 million yuan, while profits for 2023, 2024, and the first quarter of 2025 were 593 million yuan, 174 million yuan, and 102 million yuan, respectively [11]. - The company aims to integrate scientific innovation with market transformation, positioning itself as a leader in the Chinese biomanufacturing industry [11][12]. Group 3: Research Focus - Huaxi Biological's research has shifted towards glycomics and cell biology, with applications in aging intervention and regenerative medicine [12]. - The company believes that the solid foundation of scientific research will prevail after market fluctuations [12].

Group 1 - The company announced a share repurchase plan with a total expected amount between 20 million to 30 million RMB [1] - The repurchase period is set from August 28, 2024, to August 27, 2025 [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] Group 2 - As of the latest update, the company has repurchased a total of 1,482,364 shares, representing 0.731% of the total share capital [1] - The total amount spent on repurchased shares is 14,288,602.36 RMB, with a price range of 7.76 RMB to 10.53 RMB per share [1][2] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations [2]

Core Insights - The article highlights the ongoing development and innovation in the synthetic biology and biomanufacturing sectors in China, with a focus on Guangdong province, particularly Guangzhou and Shenzhen, which are leading in policy support and innovation outcomes [2][3]. Summary by Sections Industry Overview - Guangdong province's biomanufacturing industry is valued at approximately 1.3 trillion yuan, ranking third nationally, with plans to elevate the industry to a trillion-yuan scale through the "Action Plan for Accelerating the Construction of Biomanufacturing Industry Innovation High Ground" [2]. - Shenzhen has positioned synthetic biology as one of its "20+8" future industries, establishing a comprehensive support system for biomanufacturing, including a major synthetic biology infrastructure and a national innovation center [2]. Company Rankings - SynBioCon has released the "Top 500 Representative Enterprises in Biomanufacturing (Guangdong Edition)," featuring 76 companies recognized for their competitiveness based on team, core products, and diverse possibilities [3]. Upcoming Events - The "China Biomanufacturing Industry Map (2025)" will be published in August 2025, with a focus on 500 representative enterprises in biomanufacturing [1]. - The Fourth Synthetic Biology and Green Biomanufacturing Conference will be held from August 20-22, 2025, in Ningbo, Zhejiang, focusing on AI and biomanufacturing, green chemicals, new materials, future food, and agriculture [12][14].